Reducing of Defects in the Drug Tablets Production Process with DMAIC to Improve Quality - Study Case of Pharmaceutical Industry

The high defect and unstable of defects the company in 2017 amounted to 0.27% while the amount allowed by this company was 0.10%. In This research was carried out in a Pharmaceutical Industry with the purpose of reducing the product spots drug tablets, the research method uses the DMAIC stages Defin...

Full description

Saved in:
Bibliographic Details
Published in:IOP conference series. Materials Science and Engineering 2020-07, Vol.852 (1), p.12126
Main Authors: Winatie, Adha, Santoso Saroso, Dana, Hardi Purba, Humiras, Puspa Wirani, Ayu
Format: Article
Language:English
Subjects:
Control charts
Defects
Pharmaceutical industry
Pharmaceuticals
Tablets
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The high defect and unstable of defects the company in 2017 amounted to 0.27% while the amount allowed by this company was 0.10%. In This research was carried out in a Pharmaceutical Industry with the purpose of reducing the product spots drug tablets, the research method uses the DMAIC stages Define, Measure, Analyze, Improve and Control. The tools used are SIPOC diagrams, pareto diagrams, P charts, minitabs to calculate sigma levels and improvment with FMEA. The number of reject spots for tablets in 2018 was 0.28% and the sigma level was 4.63, then after analysis and DMAIC the reject rate was reduced to 0.0081% and sigma level 5.45.
ISSN:1757-8981
1757-899X
DOI:10.1088/1757-899X/852/1/012126